Xcorporeal to Present Posters on Friday, November 7th, at The American Society of Nephrology’s Renal Week 2008
November 07 2008 - 8:30AM
Business Wire
Xcorporeal, Inc. (AMEX:XCR) announced today that Victor Gura M.D.,
the Company�s Chief Scientific and Medical Officer, will deliver
two presentations at The American Society of Nephrology�s (�ASN�)
Renal Week, entitled, �The Wearable Artificial Kidney (�WAK�)
Removes and Absorbs Uric Acid, Hippuric Acid, Indoxyl Sulphate and
Indole Acetic Acid� and �The Push Pull, Double Pulsation Flow in
Opposite Phase Improves Ultrafiltration and Convective Transport
across the Dialyzer Membrane in the WAK.� Both of these
presentations continue to demonstrate the feasibility of a fully
wearable hemodialysis device with the potential to effectively
remove large molecule toxins. Dr. Gura will present today at 10.00
a.m. Eastern time. Renal Week is being held at the Pennsylvania
Convention Center in Philadelphia, PA from November 4th thru
November 9th, 2008. Additionally, Dr. Gura, along with Dr. Claudio
Ronco and Dr. Andrew Davenport, have recently published an article
entitled �A Wearable Artificial Kidney, Dream or Reality� in the
November 2008 issue of Nature Nephrology. The article may be found
at: www.nature.com/ncpneph/journal/v4/n11/full/ncpneph0929.html Dr.
Claudio Ronco is Head of the Department of Nephrology, Dialysis and
Transplantation at St. Bortolo Hospital, Vicenza, Italy and a
consultant to Xcorporeal. Dr. Davenport is a Consultant and
Honorary Senior Lecturer in the University College of London Centre
for Nephrology at the Royal Free & University College Medical
School, London, UK. The ASN is organized and operated exclusively
for scientific and educational purposes, including enhancing the
field of nephrology by advancing the scientific knowledge and
clinical practice of that discipline through stimulation of basic
and clinical investigation, providing access to new knowledge
through the publication of journals and the holding of scientific
meetings, advocating for the development of national health
policies to improve the quality of care for renal patients,
cooperating with other national and international societies and
organizations involved in the field of nephrology, and using other
means as directed by the Council of the Society. About Xcorporeal
Xcorporeal, Inc. is a medical device company developing an
innovative extra-corporeal platform technology to be used in
devices to replace the function of various human organs. The
platform leads to three initial products: a Portable Artificial
Kidney (PAK) for hospital based Renal Replacement Therapy, the
XCR-6 for home hemodialysis, and a Wearable Artificial Kidney (WAK)
for continuous ambulatory hemodialysis. For the hospital market,
Xcorporeal is developing a portable, multi-functional renal
replacement device that will offer cost-effective therapy for those
patients suffering from Acute Renal Failure, which causes a rapid
decline in kidney function. In the U.S., the disease affects more
than 200,000 patients annually with a mortality rate approaching
50%, according to a study published in the Clinical Journal of
American Society of Nephrology in 2006. The Company has completed
the development of the product prototype, which is currently
undergoing bench testing, and anticipates submitting 510(k)
filings, for the device and attendant disposable components, with
the Food and Drug Administration (FDA) during 2009. The Company
also plans to commercialize the XCR-6, a home hemodialysis device,
for the chronic End Stage Renal Disease (ESRD) market, comprised of
patients in whom the kidneys have ceased to function. The Company�s
devices are intended to combine the best attributes of currently
marketed home hemodialysis machines to offer patients convenient,
durable and truly portable treatments at home. The Company believes
its devices will provide a cost-effective alternative to current
home treatment modalities, due to their ability to offer
hemodialysis without the need for large quantities of purified
water. The Company has also completed the development of the XCR-6,
which is currently undergoing bench testing, and anticipates
submitting a 510(k) with the FDA during 2010. The Company�s WAK is
also a device for the chronic treatment of ESRD. The Company has
successfully demonstrated a prototype system that weighs less than
5 kg., is battery operated, and can be worn by an ambulating
patient while undergoing dialysis. This miniature, wearable device
is intended to enable continuous (up to 24 hours � 7 days per week)
renal replacement therapy at home. Human studies with the WAK have
been described in several scientific peer reviewed publications
including Lancet and Kidney International. It was also featured
internationally by the general press including the Los Angeles
Times, Le Figaro, Corriere de la Sera, Frankfurt Algemeiner.
Additional Company information may be found on the Internet at:
www.xcorporeal.com. Forward-Looking Statements Except for
statements of historical fact, the matters discussed in this press
release are forward looking and made pursuant to the Safe Harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements reflect numerous assumptions and
involve a variety of risks and uncertainties, many of which are
beyond the company's control that may cause actual results to
differ materially from stated expectations. These risk factors
include, among others, limited operating history, difficulty in
developing, exploiting and protecting proprietary technologies, the
risk that our technology may not be effective, uncertainty as to
the outcome of arbitration and legal proceedings, intense
competition and substantial regulation in the medical device
industry; and additional risks factors as discussed in the reports
filed by the Company with the Securities and Exchange Commission,
which are available on its website at http://www.sec.gov.
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Jul 2024 to Aug 2024
Xcorporeal, Inc. (AMEX:XCR)
Historical Stock Chart
From Aug 2023 to Aug 2024